In a study of 19 patients with glioblastoma, progression-free survival increased from 6 months to 19 months.
[OneMedForum] Immunocellular Therapeutics
The Los Angeles-based company discussed its recent clinical trials, including results from a Phase I study of ICT-107 to treat a deadly form of brain cancer called glioblastoma.
